We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street gave a muted performance last week as the S&P 500 and the Nasdaq snapped the prolonged winning streak. The S&P 500 (down 1.4%), the Dow Jones (down 1.7%) and the Nasdaq (down 1.4%) — the three big U.S. equity indexes — took a dive last week. The reason behind the fall was renewed rate hike worries.
The benchmark U.S. treasury yield was 3.77% at the start of the week, which ended at 3.74%, having hit a high of 3.80% on Jun 22, 2023. Fed Chair Jerome Powell stated last week that most central bank officials anticipate raising interest rates by the end of 2023. While the Fed decided to maintain the target range at the June policy meeting, Powell's remarks point to the tightening of the monetary policy all over again.
Median expectation for funds rates now stands at 5.6% by the end of 2023. This implies two more quarter-point hikes in the remaining meetings this year, creating a very hawkish pause. Three officials see rates rising closer to 6%. The next Fed meeting at the end of July means a lot to investors. About 80% chance of a rate hike in July is currently priced in.
While rising rate worries weighed on growth sectors like technology, several analysts also started believing that several growth stocks are overvalued. Barclays’ analyst Dan Levy and Morgan Stanley analyst Adam Jonas downgraded Tesla last week (read: Time to Offload Tesla? Inverse ETFs to Earn Profits).
Short sellers are expecting the S&P 500’s impressive 2023 rally to fizzle out. This is because of the fact that the performance of the S&P 500 wouldn’t be enthusiastic without the contribution of seven big tech companies. Some analysts believe that the AI-fueled rally might soon hit a bump.
Against this backdrop, below, we highlight a few inverse/leveraged ETFs that gained decently last week.
ETFs in Focus
Ultra Bloomberg Natural Gas 2X ETF (BOIL - Free Report) – Up 13.8%
The underlying Bloomberg Natural Gas Subindex is intended to reflect the natural gas segment of the commodities market. The index consists of futures contracts on natural gas. Higher demand from heatwave boosted natural gas prices.
The underlying MSCI Emerging Markets Index is a free float-adjusted market capitalization index designed to measure equity market performance in the global emerging markets. Rising rate worries in the United States are negative for emerging market (EM) investing as Fed rate hikes may boost the greenback, which is a negative for EM investing. Higher rates available in the United States also dull the appeal for the higher-yielding but risky EM stocks.
Real Estate Bear -3X Direxion (DRV - Free Report) – Up 11.7%
The underlying Real Estate Select Sector Index includes securities of companies from the real estate management and development and real estate investment trusts, excluding mortgage REITs. As real estate is a rate-sensitive sector and underperforms in a rising rate environment, DRV had every reason to outperform.
The underlying NYSE Arca Gold Miners Index comprises publicly traded companies that operate globally in both developed and emerging markets, and are involved primarily in the mining for gold and silver. This is another underperformer of rising rate worries. Gold prices fall if U.S. dollar rallies.
The underlying NASDAQ Biotechnology Index is a modified capitalization-weighted index that includes securities of The NASDAQ Stock Market listed companies that are classified as either biotechnology or pharmaceutical. Biotechnology stocks, being high-growth in nature, underperforms in a rising rate environment.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Best Inverse/Leveraged ETFs of Last Week
Wall Street gave a muted performance last week as the S&P 500 and the Nasdaq snapped the prolonged winning streak. The S&P 500 (down 1.4%), the Dow Jones (down 1.7%) and the Nasdaq (down 1.4%) — the three big U.S. equity indexes — took a dive last week. The reason behind the fall was renewed rate hike worries.
The benchmark U.S. treasury yield was 3.77% at the start of the week, which ended at 3.74%, having hit a high of 3.80% on Jun 22, 2023. Fed Chair Jerome Powell stated last week that most central bank officials anticipate raising interest rates by the end of 2023. While the Fed decided to maintain the target range at the June policy meeting, Powell's remarks point to the tightening of the monetary policy all over again.
Median expectation for funds rates now stands at 5.6% by the end of 2023. This implies two more quarter-point hikes in the remaining meetings this year, creating a very hawkish pause. Three officials see rates rising closer to 6%. The next Fed meeting at the end of July means a lot to investors. About 80% chance of a rate hike in July is currently priced in.
While rising rate worries weighed on growth sectors like technology, several analysts also started believing that several growth stocks are overvalued. Barclays’ analyst Dan Levy and Morgan Stanley analyst Adam Jonas downgraded Tesla last week (read: Time to Offload Tesla? Inverse ETFs to Earn Profits).
Short sellers are expecting the S&P 500’s impressive 2023 rally to fizzle out. This is because of the fact that the performance of the S&P 500 wouldn’t be enthusiastic without the contribution of seven big tech companies. Some analysts believe that the AI-fueled rally might soon hit a bump.
Against this backdrop, below, we highlight a few inverse/leveraged ETFs that gained decently last week.
ETFs in Focus
Ultra Bloomberg Natural Gas 2X ETF (BOIL - Free Report) – Up 13.8%
The underlying Bloomberg Natural Gas Subindex is intended to reflect the natural gas segment of the commodities market. The index consists of futures contracts on natural gas. Higher demand from heatwave boosted natural gas prices.
Emerging Markets Bear -3X Direxion (EDZ - Free Report) – Up 13.7%
The underlying MSCI Emerging Markets Index is a free float-adjusted market capitalization index designed to measure equity market performance in the global emerging markets. Rising rate worries in the United States are negative for emerging market (EM) investing as Fed rate hikes may boost the greenback, which is a negative for EM investing. Higher rates available in the United States also dull the appeal for the higher-yielding but risky EM stocks.
Real Estate Bear -3X Direxion (DRV - Free Report) – Up 11.7%
The underlying Real Estate Select Sector Index includes securities of companies from the real estate management and development and real estate investment trusts, excluding mortgage REITs. As real estate is a rate-sensitive sector and underperforms in a rising rate environment, DRV had every reason to outperform.
Gold Miners Bear -2X Direxion (DUST - Free Report) – Up 7.34%
The underlying NYSE Arca Gold Miners Index comprises publicly traded companies that operate globally in both developed and emerging markets, and are involved primarily in the mining for gold and silver. This is another underperformer of rising rate worries. Gold prices fall if U.S. dollar rallies.
Ultrashort Nasdaq Biotechnology -2X ETF (BIS - Free Report) – Up 5.0%
The underlying NASDAQ Biotechnology Index is a modified capitalization-weighted index that includes securities of The NASDAQ Stock Market listed companies that are classified as either biotechnology or pharmaceutical. Biotechnology stocks, being high-growth in nature, underperforms in a rising rate environment.